BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) Given Average Recommendation of “Moderate Buy” by Brokerages

BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) has been assigned a consensus rating of “Moderate Buy” from the five research firms that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $25.00.

BBOT has been the topic of a number of research reports. Canaccord Genuity Group set a $23.00 target price on shares of BridgeBio Oncology Therapeutics and gave the stock a “buy” rating in a research report on Monday. Weiss Ratings initiated coverage on shares of BridgeBio Oncology Therapeutics in a research report on Wednesday, January 14th. They set a “sell (d+)” rating on the stock. HC Wainwright raised their target price on shares of BridgeBio Oncology Therapeutics from $27.00 to $29.00 and gave the stock a “buy” rating in a research report on Friday, March 6th. Finally, Stifel Nicolaus initiated coverage on shares of BridgeBio Oncology Therapeutics in a research report on Tuesday, February 10th. They issued a “buy” rating and a $23.00 price objective on the stock.

BridgeBio Oncology Therapeutics Stock Performance

Shares of BBOT opened at $7.66 on Monday. The stock has a market capitalization of $613.64 million, a price-to-earnings ratio of -5.04 and a beta of 0.22. The business’s 50 day simple moving average is $9.15. BridgeBio Oncology Therapeutics has a 12-month low of $7.60 and a 12-month high of $14.87.

Hedge Funds Weigh In On BridgeBio Oncology Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. CIBC Private Wealth Group LLC purchased a new position in BridgeBio Oncology Therapeutics in the 4th quarter valued at $63,000. Persistent Asset Partners Ltd purchased a new stake in shares of BridgeBio Oncology Therapeutics during the 4th quarter worth $107,000. Squarepoint Ops LLC purchased a new stake in shares of BridgeBio Oncology Therapeutics during the 4th quarter worth $144,000. Quadrature Capital Ltd purchased a new stake in shares of BridgeBio Oncology Therapeutics during the 4th quarter worth $162,000. Finally, BIT Capital GmbH purchased a new stake in shares of BridgeBio Oncology Therapeutics during the 4th quarter worth $313,000. 54.89% of the stock is currently owned by hedge funds and other institutional investors.

BridgeBio Oncology Therapeutics Company Profile

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.